- |||||||||| aripiprazole / Generic mfg., cabergoline / Generic mfg., bromocriptine / Generic mfg.
Review, Journal: Drug induced hypoprolactinemia. (Pubmed Central) - Dec 7, 2024
These patients warrant careful evaluation for comorbidities. This review aims to increase awareness about the potentially detrimental effects of drug-induced hypoprolactinemia, which should be considered in clinical practice decisions.
- |||||||||| aripiprazole / Generic mfg., cabergoline / Generic mfg.
Review, Journal: Cardiometabolic effects of hypoprolactinemia. (Pubmed Central) - Dec 7, 2024
This evidence has been collected mainly in patients on chronic treatment with dopamine agonists for PRL excess due to a PRL-secreting pituitary tumour, and less frequently in those receiving the atypical antipsychotic aripiprazole...Nevertheless, current knowledge still lacks an accurate biochemical definition of hypoprolactinemia, since no clear PRL threshold has been established to rule in the diagnosis of PRL deficiency enabling early identification of those individual subjects with increased cardiovascular risk directly ascribable to the hormonal imbalance. The current review article focuses on the effects of hypoprolactinemia on the modulation of body weight, gluco-insulinemic and lipid profile, and provides latest knowledge about potential cardiovascular outcomes of hypoprolactinemia.
- |||||||||| cabergoline / Generic mfg., bromocriptine / Generic mfg.
Retrospective data, Journal: Does hyperprolactinemia treatment affect pregnancy and perinatal outcomes? (Pubmed Central) - Nov 16, 2024
Preconception metabolic management should be recommended to reduce the risk of gestational and type 2 diabetes mellitus. Regardless of the type of previous drug treatment with dopamine agonists, hyperprolactinemia does not alter obstetric outcomes.
- |||||||||| cabergoline / Generic mfg.
Journal: Effect of Cabergoline on weight and glucose metabolism in patients with acromegaly. (Pubmed Central) - Nov 13, 2024
Our results confirm the efficacy of CAB in providing a significant improvement in the biochemical disease control but do not demonstrate a marked benefit on glucose metabolism of acromegaly patients. In such patients, CAB appears to have a rapid effect on weight and BMI, with significant changes noticeable as early as 6
- |||||||||| cabergoline / Generic mfg.
Clinical, Journal: The effects of cabergoline in the presurgical and recurrence periods of Cushing's disease patients. (Pubmed Central) - Nov 13, 2024
The normalization of 24-h UC and LNSC occurred in approximately 30% of all patients, mainly in those who used CAB for the recurrence of CD. Despite the small number of subjects in the CABi subgroup, the absence of hormone control in this subgroup discourages the use of this medication as primary therapy or as a preoperative treatment option.
- |||||||||| Somavert (pegvisomant) / Pfizer, Signifor (pasireotide) / Recordati
Cost-Utility of Acromegaly Second Line Pharmacological Treatments in Adult Patients in France () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2451;
The updated model aims to offer a more thorough and comprehensive view of the cost-utility of second-line pharmacological treatments in acromegaly. Beyond clinical data, this analysis broadens our perspective within a framework where costs of treatments are rising, and healthcare system financing is more challenging.
- |||||||||| cabergoline / Generic mfg.
Journal: Increased Cardiometabolic Risk in Men with Hypoprolactinemia: A Pilot Study. (Pubmed Central) - Oct 26, 2024
Although cabergoline dose reduction did not cause statistically significant changes in the remaining anthropometric parameters and intima-media thickness, six months later, they did not differ from those observed in the remaining study groups. Our findings suggest that iatrogenic hypoprolactinemia is associated with increased cardiometabolic risk, which is reversible and resolves after the normalization of prolactin levels.
- |||||||||| Permax (pergolide) / Eli Lilly
Review, Journal: Ergot alkaloid control in biotechnological processes and pharmaceuticals (a mini review). (Pubmed Central) - Oct 23, 2024
Both rapid methods and liquid chromatography remain in demand in routine practice, with rapid analysis evolving toward higher accuracy owing to improved analytical performance and new equipment. New composite electrochemical sensors (including disposable sensors) have demonstrated potential for real-time process control.
- |||||||||| cabergoline / Generic mfg.
Journal, HEOR: Budget impact analysis of cabergoline for medical treatment of Cushing's disease in Brazil. (Pubmed Central) - Oct 18, 2024
The estimated budget impact of adding cabergoline to the formulary for CD treatment within the Brazilian SUS would be about BRL $6 million. While cost savings cannot be expected, the budget impact of adding cabergoline would be lower than that of adding other treatment options for CD.
- |||||||||| Signifor (pasireotide) / Recordati
Journal: Pituitary gigantism due to a novel AIP germline splice-site variant. (Pubmed Central) - Oct 11, 2024
IGF-I concentrations decreased but did not normalize. We discovered a novel germline single nucleotide variant in the splicing donor region of intron 2 of the AIP gene (NM_003977.4:c.279+1 G>A), classified as likely pathogenic according to the American College of Medical Genetics and Genomics guidelines.
- |||||||||| cabergoline / Generic mfg.
Journal: Aftercare following second trimester abortion procedures. (Pubmed Central) - Oct 3, 2024
We discovered a novel germline single nucleotide variant in the splicing donor region of intron 2 of the AIP gene (NM_003977.4:c.279+1 G>A), classified as likely pathogenic according to the American College of Medical Genetics and Genomics guidelines. Clinical practices and healthcare systems should prioritize the aftercare experience including the management of breast symptoms, bereavement, disposition of fetal remains, and follow-up care.
- |||||||||| cabergoline / Generic mfg.
Journal: L-Dopa Might Be Insufficient to Suppress Development of Prolactinomas in Dihydropteridine Reductase-Deficiency Patients. (Pubmed Central) - Sep 30, 2024
Cabergoline has a stronger affinity for the D2R receptor and longer half-life than L-Dopa, leading to lactotroph apoptosis, tumor shrinkage, and rapid and maintained normalization of PRL levels, with a better side-effect profile. Patients with DHPR deficiency need to be actively monitored for symptomatic hyperprolactinemia, as L-Dopa monotherapy is insufficient to suppress PRL secretion, leading to lactotroph hypertrophy and proliferation over time and development of prolactinomas in later life.
- |||||||||| Mifeprex (mifepristone) / Danco Laboratories
Clinical guideline, Journal: Fetal death: Expert consensus from the College of French Gynecologists and Obstetricians (Pubmed Central) - Sep 28, 2024
It is not recommended to prescribe aspirin (Weak recommendation; Very low quality of evidence)...In the event of fetal death, it is recommended that mifepristone 200mg be prescribed at least 24hours before induction, to reduce the delay between induction and delivery (Low recommendation...It is suggested to prescribe cabergoline immediately in the postpartum period in order to avoid lactation, whatever the gestational age, after discussing the side effects of the treatment with the patient (Expert opinion)...If fetal death occurs in a monochorionic twin pregnancy, it is suggested to contact the referral competence center, in order to urgently look for signs of acute fetal anemia on ultrasound in the surviving twin, and to carry out weekly ultrasound monitoring for the first month. It is suggested not to induce birth immediately.
- |||||||||| Review, Journal: Medical treatment of acromegaly - When the tumor size matters: A narrative review. (Pubmed Central) - Sep 15, 2024
Therefore, an individual approach is necessary in the treatment of patients with acromegaly, based on repeated insight to their clinical, biochemical, pathological and imaging characteristics. In this review, we summarize and comment how pituitary tumor size is affected by the treatment with all currently available drugs in acromegaly: long-acting somatostatin receptor ligands of the first generation (octreotide LAR and lanreotide autogel) and the second generation (pasireotide-LAR), as well as pegvisomant (PEG) and cabergoline (CAB).
- |||||||||| cabergoline / Generic mfg.
Journal: Intraoperative Takotsubo Syndrome. (Pubmed Central) - Sep 1, 2024
Perioperative combination of cabergoline and oxymetazoline induced intraoperative hypertension, pulmonary edema, and Takotsubo stress cardiomyopathy. To our knowledge, this is the first reported case in the literature of intraoperative Takotsubo cardiomyopathy, potentially linked to the specific combination of intraoperative cabergoline and oxymetazoline.
- |||||||||| cabergoline / Generic mfg., amiodarone / Generic mfg.
Journal: Nonarteritic Anterior Ischemic Optic Neuropathy and Semaglutide: What is This All About? (Pubmed Central) - Aug 20, 2024
The clinical description of NAION was not known until 1935 when C. Miller Fischer thoroughly described it. Briefly, NAION is a rare (2.5-11.8 per 1,00,000 cases in men above 50 years) but serious condition that causes sudden painless loss of vision due to ischemia of the optic nerve.1 It is more common in Caucasians compared with Asians and is associated with various risk factors such as hypertension, type 2 diabetes (T2D), smoking, hyperlipidemia, obesity, obstructive sleep apnea, small optic nerve cup ("disk at risk"), optic nerve drusen, and certain drugs, especially phosphodiesterase type 5 inhibitors (PDE-5I), amiodarone, and cabergoline.2 Although the clinical development programs and real-world studies of semaglutide [a glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for the treatment of T2D and obesity] did not report any significant increase in the risk of NAION, a recent retrospective cohort study suggested a possible link between NAION and semaglutide.3 This editorial briefly summarizes the current knowledge about NAION and its relation to metabolic disorders, cardiovascular, and antidiabetes drugs and puts a perspective concerning semaglutide.
- |||||||||| cabergoline / Generic mfg.
Review, Journal: Clinical and therapeutic implications of cavernous sinus invasion in pituitary adenomas. (Pubmed Central) - Aug 10, 2024
Tumor regrowth usually requires surgical reintervention, sometimes combined with radiotherapy or radiosurgery which is applied despite their benign nature. Unraveling the molecular pathways driving invasive behavior of pituitary adenomas and their tropism to the cavernous sinuses is the key for developing efficient innovative treatment modalities that could reduce the need for repeated surgery or radiotherapy.
- |||||||||| cabergoline / Generic mfg.
Journal: A Non-Secreting Pituitary Adenoma That Changed to a Prolactinoma. (Pubmed Central) - Jul 26, 2024
This case report represents an exception to the paradigm that in the presence of a macroadenoma and normal PRL levels (avoiding the "hook effect"), a prolactinoma can be discarded. Moreover, it stresses the importance of comprehensive, regular, and lifelong surveillance of patients with NFPAs and the close monitoring of serum PRL.
- |||||||||| cabergoline / Generic mfg.
Review, Journal, Real-world evidence, Real-world: Real-world value of cabergoline in the treatment of acromegaly. (Pubmed Central) - Jul 21, 2024
Combination treatment with the GH receptor antagonist pegvisomant can also be beneficial. The inexpensive, well-tolerated and convenient oral administration of cabergoline makes it an attractive medical therapy for active acromegaly.
- |||||||||| cabergoline / Generic mfg.
Prolactin contributes to endometriosis and comorbid migraine-like pain (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_1963;
High systemic and local PRL sensitize sensory neurons through upregulation of PRLR-S expression resulting in endometriosis-associated pelvic pain and migraine-like pain from normally innocuous stimuli. Together, these findings highlight opportunities for treatment in endometriosis and comorbid disorders, including the use of dopamine D2 receptor agonists for migraine and potential development of PRL or PRLR antibodies, which would sequester both local and systemic PRL for treatment of both pelvic pain and migraine.
- |||||||||| cabergoline / Generic mfg., clomifene citrate / Generic mfg.
Journal: Long-term use of clomiphene in male macroprolactinomas with persistent hypogonadism. (Pubmed Central) - Jul 13, 2024
This can have overbearing effects on the psychology and function of the individual, thus making early diagnosis and precise management important. CC should be seen as a safe treatment option for men with macroprolactinoma and persistent hypogonadism.
- |||||||||| cabergoline / Generic mfg.
Journal: Apoplexy of a giant clival ectopic prolactinoma: A very rare case report. (Pubmed Central) - Jun 16, 2024
Pituitary apoplexy in ectopic pituitary neuroendocrine tumor is extremely rare. Therefore, in case of unusual localization of pituitary neuroendocrine tumor, a thorough follow-up is necessary to detect complications and ensure early management.
- |||||||||| cabergoline / Generic mfg.
Journal: Dopamine receptor agonist cabergoline promotes immunogenic phenotype in human monocyte-derived dendritic cells. (Pubmed Central) - Jun 14, 2024
and IL-12 in comparison to the mDC control group. Our findings revealed that cabergoline as an immunomodulatory agent can relatively shift DCs into an immunogenic state, and there is a requirement for further investigations to evaluate the effects of cabergoline-treated DCs on the T cell responses in vitro, and also in various diseases including cancer in animal models.
- |||||||||| letrozole / Generic mfg.
Observational data, Retrospective data, Journal: Letrozole and ovarian hyperstimulation syndrome: Retrospective cross-sectional study. (Pubmed Central) - Jun 13, 2024
The parameters of OHSS severity, hospitalization rates, and the need for albumin prescription showed no significant differences between the groups. Recent study indicates that incorporating letrozole into the treatment of GnRH antagonists and cabergoline does not reduce the OHSS severity.
- |||||||||| Somavert (pegvisomant) / Pfizer, Signifor (pasireotide) / Recordati
Journal: Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE). (Pubmed Central) - Jun 4, 2024
Moreover, at odds with consensus guidelines, other monotherapies for acromegaly appear to have a marginal role as compared to combination therapies as extrapolated from PTCOE practice data. Presence of uncontrolled patients in each treatment category suggest that further optimization of medical therapy, as well as use of other therapeutic tools such as radiosurgery may be needed.
|
